Fatty Liver Disease: Can It Be Reversed and What’s the Role of Surgery?

A lot of people find out about fatty liver the same way. They went for an abdominal ultrasound, maybe for stomach discomfort, maybe as part of a routine checkup and the report came back mentioning “hepatic steatosis” or “fatty changes in the liver.” The doctor mentioned it briefly, possibly suggested some lifestyle changes, and that was that.

Some people look it up and find reassuring information. Others find alarming information. Most find a confusing mix of both and leave not quite sure whether this is something to take seriously or something that’ll sort itself out.

The honest answer is that it depends on where on the spectrum the fatty liver sits. For some people, it’s a reversible condition that responds well to lifestyle changes. For others, it’s a progressive disease that needs active management to prevent serious liver damage over time. And surgery, while not a treatment for fatty liver itself, plays a specific role in certain situations that’s worth understanding.

What Is Fatty Liver Disease?

Fatty liver disease medically called hepatic steatosis, is a condition where fat accumulates within liver cells beyond a normal threshold. A small amount of fat in the liver is normal. When fat exceeds roughly five percent of the liver’s weight, it’s classified as fatty liver.

There are two main types:

Alcoholic fatty liver disease (AFLD) – caused by excessive alcohol consumption, which disrupts the liver’s ability to metabolise fat normally. Alcohol-related liver disease exists on its own spectrum, from simple steatosis through to alcoholic hepatitis and cirrhosis.

Non-alcoholic fatty liver disease (NAFLD) – fat accumulation in people who drink little or no alcohol. This is the more common and rapidly growing form, and it’s the one most relevant to the majority of patients who find it on an ultrasound without an obvious explanation.

NAFLD itself exists on a spectrum:

Simple steatosis – fat in the liver cells, without significant inflammation or damage. The liver is working adequately. This is the mildest and most common form.

Non-alcoholic steatohepatitis (NASH) – fat accumulation accompanied by inflammation and liver cell damage. This is the more serious form. The inflammation causes progressive injury to the liver over time.

Fibrosis – repeated cycles of inflammation and injury cause scar tissue to form in the liver. As fibrosis progresses through stages (F1 to F4), the liver’s architecture and function are increasingly compromised.

Cirrhosis – advanced, widespread scarring that disrupts the liver’s structure and significantly impairs its function. Cirrhosis is largely irreversible and is associated with serious complications, portal hypertension, fluid accumulation in the abdomen, liver failure, and an increased risk of liver cancer.

Understanding where someone sits on this spectrum is the most important factor in determining how urgently the condition needs to be addressed and what management looks like.

How Common Is It And Why Is It Increasing?

NAFLD is one of the most common liver conditions worldwide and its prevalence is rising sharply, closely tracking the global increase in obesity, type 2 diabetes, and metabolic syndrome.

In urban India and Chennai is no exception, the combination of increasingly sedentary lifestyles, dietary shifts toward refined carbohydrates and processed food, and a genetic predisposition to insulin resistance in South Asian populations has made NAFLD particularly prevalent. Studies suggest that Indians develop metabolic complications at lower BMI thresholds than Western populations, meaning fatty liver can be present in people who don’t appear significantly overweight by general standards.

A significant proportion of people with NAFLD don’t know they have it. The condition is often asymptomatic in the early stages, the liver doesn’t have many pain receptors, and simple steatosis doesn’t typically cause noticeable symptoms. It’s found incidentally, or not found at all until it’s progressed.

What Causes Fatty Liver in People Who Don’t Drink?

The central driver of NAFLD is insulin resistance, a state where the body’s cells don’t respond normally to insulin, causing the liver to accumulate fat as part of a broader metabolic disruption.

Contributing factors include:

• Obesity – particularly central adiposity, where fat accumulates around the abdomen and visceral organs
• Type 2 diabetes or pre-diabetes – insulin resistance is the shared mechanism
• High triglycerides and dyslipidaemia – elevated blood fats contribute to fat deposition in the liver
• Metabolic syndrome – the combination of abdominal obesity, elevated blood sugar, high triglycerides, low HDL cholesterol, and high blood pressure
• Sedentary lifestyle – physical inactivity worsens insulin resistance independently of weight
• Diet – high in refined carbohydrates, added sugar (particularly fructose), saturated fat, and ultra-processed food
• Rapid weight loss – paradoxically, losing weight very quickly can worsen liver inflammation temporarily before improving it
• Polycystic ovary syndrome (PCOS) – associated with insulin resistance and higher NAFLD prevalence in women
• Certain medications – corticosteroids, tamoxifen, amiodarone, and others can cause drug-induced fatty liver
• Genetic factors – certain gene variants (particularly in the PNPLA3 gene) increase susceptibility to NAFLD and its progression

Can Fatty Liver Be Reversed?

This is the question most patients want answered first and the encouraging answer is yes, for early-stage disease.

Simple steatosis is reversible. Fat accumulation in the liver cells, without significant inflammation or fibrosis, responds well to the interventions that address insulin resistance and metabolic health. Weight loss, dietary change, and increased physical activity can reduce liver fat content measurably, sometimes dramatically, over weeks to months.

Studies consistently show that losing five to ten percent of body weight produces meaningful reductions in liver fat. Losing more than ten percent has been associated with improvement in liver inflammation and even early fibrosis in some cases. This doesn’t require extreme or rapid weight loss a sustained, moderate reduction achieved through dietary change and exercise is what produces the most durable improvement.

NASH with early fibrosis can improve. The inflammatory component of NASH and early fibrosis, can also improve with the right interventions, though it takes longer and requires more sustained effort than reversing simple steatosis. Regular monitoring is important to track whether the liver is improving or progressing.

Advanced fibrosis and cirrhosis are largely irreversible. Once the liver has developed significant scarring particularly at the cirrhosis stage, the structural changes are not reversible in the way that fat accumulation is. Management at this stage focuses on slowing further progression, preventing complications, and monitoring for liver cancer. This is why catching fatty liver early matters enormously the window for reversal exists in the earlier stages.

What Does Reversal Actually Look Like in Practice?

When patients hear “lifestyle changes,” it can sound vague and unconvincing, as though the doctor is saying there’s nothing specific to do. The reality is more concrete.

Dietary change – the most impactful single intervention. The dietary pattern most consistently associated with improvement in NAFLD is one that reduces refined carbohydrates and added sugar significantly, reduces saturated fat, increases dietary fibre, and emphasises whole foods vegetables, legumes, whole grains, lean protein, and healthy fats from sources like nuts and olive oil. The Mediterranean dietary pattern has the strongest evidence base for liver health specifically.

Reducing fructose is particularly relevant fructose, found in added sugar, sugary drinks, and processed foods, is processed almost exclusively in the liver and directly contributes to fat synthesis there. Cutting sugary drinks, including fruit juice is one of the more impactful specific changes.

Physical activity – exercise improves insulin sensitivity and reduces liver fat independently of weight loss. Even without significant weight change, regular aerobic exercise, thirty to forty-five minutes most days produces measurable reductions in liver fat over weeks to months. Resistance training has complementary benefits through its effect on muscle mass and insulin sensitivity.

Weight management – for patients who are overweight or obese, even a five percent reduction in body weight produces measurable liver benefit. The approach should be gradual and sustainable rather than rapid, crash dieting can cause a temporary inflammatory response in the liver even as it reduces weight.

Treating metabolic comorbidities – managing blood sugar in diabetes, treating dyslipidaemia, controlling blood pressure. These aren’t separate from fatty liver management, they’re part of the same metabolic picture, and improving them improves the liver environment.

Alcohol – even in NAFLD (which by definition isn’t alcohol-related), moderate to heavy alcohol consumption worsens liver inflammation. Reducing or eliminating alcohol is part of comprehensive management.

Medications – there’s currently no approved drug specifically for NAFLD or NASH, though several are in late-stage trials. Vitamin E has some evidence in non-diabetic NASH patients. GLP-1 receptor agonists, medications used for diabetes and weight management like semaglutide, have shown promising results in reducing liver fat and inflammation in recent trials and are increasingly used in clinical practice where appropriate. Pioglitazone is sometimes used in diabetic patients with NASH. These are specialist decisions based on individual circumstances.

How Is Progress Monitored?

Liver function tests – blood tests measuring liver enzymes (ALT, AST) are a useful but imperfect marker. They can be elevated in active liver inflammation and can normalise with improvement, but normal enzymes don’t guarantee normal liver, particularly in simple steatosis where enzymes are often normal despite fat accumulation.

Ultrasound – can detect the presence and approximate degree of fatty change but isn’t sensitive enough to detect early fibrosis or distinguish NASH from simple steatosis reliably.

FibroScan (transient elastography) – a specialised ultrasound-based technique that measures liver stiffness as an indirect marker of fibrosis. Non-invasive, quick, and increasingly available. Provides a more accurate assessment of fibrosis stage than standard ultrasound.

Blood-based fibrosis markers – tests like the FIB-4 index (using age, ALT, AST, and platelet count) and the NAFLD fibrosis score provide non-invasive estimates of fibrosis risk.

Liver biopsy – the gold standard for staging NAFLD/NASH, providing definitive information about the degree of fat, inflammation, and fibrosis. Invasive and not without risk, so it’s reserved for cases where non-invasive assessment is inconclusive and the result would meaningfully change management, typically when significant fibrosis is suspected and needs to be confirmed.

Where Does Surgery Come In?

Surgery isn’t a treatment for fatty liver itself. The condition is metabolic, it’s treated through metabolic interventions. But surgery intersects with fatty liver disease in several important ways.

Bariatric Surgery for Severe Obesity and NAFLD

For patients with severe obesity (BMI above 35-40) and NAFLD, bariatric surgery, weight loss surgery is one of the most effective interventions available. Procedures like laparoscopic sleeve gastrectomy or Roux-en-Y gastric bypass produce significant and sustained weight loss that dramatically improves NAFLD and NASH in a large proportion of patients.

Studies show that bariatric surgery resolves NASH in the majority of patients, with improvement in liver inflammation and even regression of fibrosis in many cases. The magnitude of metabolic improvement from bariatric surgery exceeds what’s achievable through lifestyle change alone for most severely obese patients.

Bariatric surgery for fatty liver isn’t appropriate for everyone, patient selection requires careful assessment of BMI, metabolic comorbidities, previous weight loss attempts, and overall surgical fitness. But for the right patient, it represents a genuinely disease-modifying intervention rather than just a cosmetic or weight-related one.

Pre-Operative Assessment in Patients With Fatty Liver

Fatty liver has direct implications for any surgical procedure, not just bariatric surgery. A significantly fatty or inflamed liver is more fragile during surgery. It bleeds more easily, is more susceptible to injury during procedures involving the upper abdomen, and recovers more slowly from the physiological stress of surgery and anaesthesia.

For patients undergoing any significant abdominal operation who are known to have NAFLD particularly NASH, the surgical team needs to be aware. In some cases, optimising metabolic control and liver health in the weeks before an elective procedure reduces surgical risk.

Gallbladder Surgery in Fatty Liver Patients

As discussed in the Cholesterol, Fatty Liver and Gallbladder blog, these three conditions frequently occur together. Patients with NAFLD have a higher risk of gallstone disease, from the same insulin resistance and cholesterol metabolism disruption that causes fatty liver.

When gallstones become symptomatic in a patient with fatty liver, laparoscopic cholecystectomy is the treatment, with the awareness that the liver may be enlarged and more fragile than in a patient without fatty liver disease. An experienced surgeon adapts the approach accordingly.

Liver Resection for Liver Cancer

NAFLD particularly when it progresses to cirrhosis, increases the risk of hepatocellular carcinoma (liver cancer). Regular surveillance with ultrasound and AFP (alpha-fetoprotein) blood tests is recommended for patients with established cirrhosis from any cause, including NAFLD-related cirrhosis.

When liver cancer is detected at an early stage in a patient with fatty liver-related liver disease, surgical resection removing the affected portion of the liver, is potentially curative. The feasibility depends on the size and location of the tumour and the functional reserve of the remaining liver, which is where the degree of underlying liver disease becomes critical.

Liver Transplantation

For patients who progress to end-stage liver disease from NASH-related cirrhosis liver failure, portal hypertension, recurrent ascites, encephalopathy, liver transplantation is the definitive treatment. NASH has become one of the leading indications for liver transplantation in many countries as its prevalence has grown.

Transplantation is a major undertaking with strict selection criteria, long waiting lists, and lifelong immunosuppression afterward. It’s the outcome that comprehensive early management of NAFLD is aimed at preventing.

Final Thoughts

Fatty liver disease found incidentally on an ultrasound isn’t a reason to panic, but it is a reason to act. In the early stages, it’s a reversible condition that responds meaningfully to the right interventions. In the later stages, it’s a progressive disease with serious long-term consequences that become harder to address the further they advance.

The gap between “found early and managed well” and “found late after significant fibrosis has developed” is largely determined by what happens in the years between the diagnosis and the point where symptoms eventually force the issue.

Catching it on an ultrasound is an opportunity. Using that opportunity, with the right dietary changes, physical activity, metabolic management, and appropriate monitoring is what determines the long-term trajectory.

Our team evaluates fatty liver findings in the context of overall metabolic health advising on appropriate lifestyle interventions, monitoring, and when surgical options like bariatric surgery or gallbladder management are relevant to the individual picture. If you’ve been told you have fatty liver and want to understand what it means and what to do about it, come in for a consultation.